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Lipid raftThe binding of lipopolysaccharides (LPS) to macrophages results in inﬂammatory responses. In extreme
cases it can lead to endotoxic shock, often resulting in death. A broad range of antioxidants, including
tocopherols, can reduce LPS activity in vitro and in vivo. To elucidate the underlying mechanisms of their
action, we investigated the effect of the sodium salt of γ-L-glutamyl-S-[2-[[[3,4-dihydro-2,5,7,8-
tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl]oxy]carbonyl]-3-[[2-(1H-indol-3-yl)ethyl]
amino]-3-oxopropyl]-L-cysteinylglycine (ESeroS-GS), a novel α-tocopherol derivative, on LPS-induced
inﬂammation in vitro and in vivo. ESeroS-GS reduced the transcription of TNF-α, IL-1β, IL-6 and iNOS genes
in a dose-dependent manner in RAW264.7 macrophages, and inhibited the release of these inﬂammatory
factors. In addition, ESeroS-GS inhibited LPS-induced mortality in a mouse sepsis model. Electrophoretic
mobility shift assays (EMSA) and reporter gene assays revealed that ESeroS-GS down-regulated the
transcriptional activity of NF-κB. By analyzing the partitioning of CD14 and Toll-like receptor 4 (TLR-4) in
cell membrane microdomains, we found that ESeroS-GS attenuates the binding of LPS to RAW264.7 cells
via interfering with the relocation of CD14 and TLR-4 to lipid rafts, blocking the activation of interleukin-1
receptor-associated kinase 1 (IRAK-1), and inhibiting the consequent phosphorylation of TAK1 and IKKα/β,
which together account for the suppression of NF-κB activation. Taken together, our data suggest that
ESeroS-GS can modulate LPS signaling in macrophages by impairing TLR-4 complex assembly via a lipid
raft dependent mechanism.iomacromolecules, Institute of
ad, Chaoyang District, Beijing
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Inﬂammation is a beneﬁcial host response to foreign challenge or
tissue injury, protecting thehost against noxiousmaterials and facilitating
the restoration of tissue structure and function. Mononuclear phagocytes
(monocytes and macrophages) exert key functions during this response
which is vital for the recognition and elimination of invasive microbial
pathogens [1–3]. Some bacterial components such as lipopolysaccharides
(LPS; also termed endotoxin) can trigger the inﬂammatory response of
mononuclear phagocytes. LPS is an integral structural component of the
outer membrane of Gram-negative bacteria [4,5] and can be releasedduring cell division, cell death, or as a result of antibiotic treatment against
bacterial infection [6,7]. Upon its release, LPS is recognized by mononu-
clear phagocytes and activates innate immunity.
The onset of LPS activation of macrophages occurs when LPS
(through its toxic entity, lipid A) binds to LPS binding protein (LBP),
accelerating the binding of LPS to CD14, the primary receptor of LPS,
which is expressed mainly in macrophages [8]. The LPS–CD14
complex initiates intracellular signaling by interacting with the
transmembrane protein Toll-like receptor 4 (TLR-4) [9]. Assembly
and activation of the TLR-4 complex initiates early processes of
proinﬂammatory immune responses that help to strengthen the
processes of innate and adaptive immunity, in which the nuclear
factor κ-B (NF-κB) pathway plays many important roles. Activation of
the NF-κB transcription factor is thought to act as a “master switch”
for inﬂammation by regulating the transcription of genes involved in
immunity and inﬂammation [10,11].
The NF-κB family of transcription factors includes homo- or
heterodimers of p50, p52, p65 (RelA), c-Rel, and RelB. In the classical
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subunit, inhibitor of NF-κB (IκB), which prevents NF-κB subunits from
leaving the cytosol. Upon activation by LPS and other agents, IκB is
primarily phosphorylated by the IκB kinase (IKK) complex, resulting
in the subsequent ubiquitination and degradation of IκB proteins via
the proteosomal pathway. Degradation of IκB results in the release of
NF-κB transcription factors, and free NF-κB is translocated to the
nucleus where it binds to NF-κB binding sites in the promoter regions
of target genes inducing their transcription [12]. The activation of NF-
κB by LPS exposure in macrophages signiﬁcantly enhances the
secretion of proinﬂammatory cytokines such as tumor necrosis
factor-α (TNF-α) and interleukin-1β (IL-1β) [13]. The expression of
inﬂammation-related genes, such as inducible nitric oxide synthase
(iNOS) [14] and cyclooxygenase-2 (COX-2) [15], is also induced.
Although proinﬂammatory cytokine secretion and inﬂammation-
related gene expression in macrophages induced by LPS activation is
essential for the development of the local inﬂammatory response,
unbalanced production or overproduction of such proinﬂammatory
factors (cytokines, nitric oxide, and prostaglandins) may lead to septic
shock characterized by endothelial damage, loss of vascular tone,
coagulopathy, and multiple system organ failure, often resulting in
death [16]. Experimental models of sepsis have shown increased
levels of TNF in the serum [17]. Hence, activation of macrophages
must be tightly regulated, and identiﬁcation of compounds with
modulatory effects on activated macrophages represents an area of
great relevance for these diseases.
It has been well documented that a broad range of antioxidants
(including melatonin, ﬂavonoids, polyphenols, and tocopherols) can
abolish LPS activity and act as anti-inﬂammatory agents in vitro and in
vivo [18–21]. α-Tocopherol inhibits the production of proinﬂammatory
cytokines (TNF-α, macrophage inﬂammatory protein-2, and IL-1β) in
neutrophils exposed to LPS, probably via a NF-κB-dependent mecha-
nism [22]. In vitro treatment of humanmonocytes with 2,7,8-trimethyl-
2-(β-carboxyethyl)-6-hydroxychroman (γ-CEHC; a metabolite of γ-
tocopherol) inhibits LPS-induced degradation of IκB and JNK activation
[23]. Dietary supplementation of mixed tocopherols in humans [23] or
inmice [24] effectively inhibits the LPS-induced inﬂammatory response
in vivo. These lines of evidence suggest that tocopherols might regulate
the activation of macrophages and the subsequent production of
proinﬂammatory factors via a redox-dependent NF-κB signaling
pathway. However, the exact mechanisms are not yet clear.
Recently, it has been hypothesized that lipid raft microdomainsmay
act as targets for antioxidants. The plasma membrane of cells was once
believed to be homogeneous, but it is now clear that lipids in the cell
membrane are organized in very small domains that are essential for
cellular function. Lipid rafts are small membrane domains (less than 50
nm diameter) composed of glycosphingolipids and cholesterol, within
which associated proteins are likely to be concentrated [25,26].
Although lipid rafts are known to exist, their physiological signiﬁcance
is not yet clear. One of themost widely appreciated roles of lipid rafts is
in the recruitment and concentration of molecules involved in cellular
signaling [27]. The accumulation of receptors and the downstream
signal transduction machinery in lipid rafts seems to enhance signaling
efﬁciency by providing a concentrating effect [28]. Thus, lipid raft
microdomains can act as a platform for signal transduction [29–31].
Lipid rafts also play important roles in the immune system
[32–34]. In macrophages, receptor molecules that are implicated in
lipopolysaccharide (LPS)-cellular activation, such as CD14, heat shock
protein (HSP) 70, HSP 90, chemokine receptor 4 (CXCR4), growth
differentiation factor 5 (GDF5) and Toll-like receptor 4 (TLR-4), are
present in microdomains following LPS stimulation [32]. CD14, the
recognition receptor of LPS, is a GPI-anchored protein that does not
have a cytoplasmic domain [8,35,36]. Following complex binding of
LPS/LPB to CD14, the assembly of the TLR-4 complex, composed of
CD14, TLR-4, myeloid differentiation protein 2, and HSP70, occurs in
the lipid raft [37].Since lipid raft microdomains act as platforms for macrophage
activation, which might be regulated by antioxidants, the overall
objective of the present study was to characterize the fundamental
cellular mechanisms that link tocopherols and NF-κB activation in lipid
rafts.We investigated the effect of the sodiumsalt ofγ-L-glutamyl-S- [2-
[[[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-
1-benzopyran-6-yl]oxy]carbonyl]-3-[[2-(1H-indol-3-yl)ethyl]amino]-
3-oxopropyl]-L-cysteinylglycine (ESeroS-GS), a novel α-tocopherol
derivative, on LPS-induced inﬂammation in vitro and in vivo, and
hypothesized the underlying mechanisms.
2. Materials and methods
2.1. Chemicals and antibodies
The sodium salt of γ-L-glutamyl-S-[2-[[[3,4-dihydro-2,5,7,8- tet-
ramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl]oxy]
carbonyl]-3-[[2-(1H-indol-3-yl)ethyl]amino]-3-oxopropyl]-L-cystei-
nylglycine (ESeroS-GS) was obtained from Senju Pharmaceutical Co.
Ltd. (Osaka, Japan). Lipopolysaccharide (LPS; from E. coli 026:B6), FITC-
LPS and α-tocopherol were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Dulbecco's modiﬁed Eagle's medium (DMEM), fetal bovine
serum, cell culture supplements and Lipofectamine 2000TM were
products of Invitrogen (Shanghai, China). Antibodies against phospho-
TAK1 (Thr184/187), phospho-IKKα/β (Ser176/180), phospho-IκB-α
(Ser32), phospho-IRAK-1 (Thr209), TAK1, IKKα/β, IκB-α, IRAK-1, CD14
and TLR-4 were purchased from Cell Signaling Technology (Danvers,
MA, USA). Antibodies against iNOS, p65/RelA and p50 were purchased
from BD Transduction Laboratories (San Jose, CA, USA). Other reagents
were manufactured in China and were of analytical grade.
2.2. Cell culture and LPS exposure
RAW264.7 murine macrophages were obtained from the Chinese
TypeCultureCollection (CTCC, Shanghai, China) andweremaintained in
DMEM supplemented with 2mM L-glutamine, 100 U/ml penicillin, 100
μg/ml streptomycin, and 10% heat-inactivated fetal bovine serum (v/v)
[21]. Cells were incubated at 37 °C under a humidiﬁed atmosphere
containing 5% CO2/95% air. RAW264.7 macrophages (50% conﬂuence)
were stimulated with LPS (1 μg/ml) in serum-free DMEM for the times
indicated. Cells were pretreated with ESeroS-GS (5, 20 or 50 μM) for 30
min before LPS exposure in some experiments, as indicated.
2.3. Mice experiments
Male C57BL/6J mice weighing 18–22 g were purchased from the
Vital River Experimental Animal Center (Beijing, China) and used in
accordance with the regulations approved by the Institutional Animal
Care and Use Committee of Institute of Biophysics, Chinese Academy
of Sciences (IACUC-IBP). Mice were randomly divided into 5 groups
(12miceper group). Group1micewere injected i.p.with saline; group2
mice were injected i.p. with ESeroS-GS (100 mg/kg of body weight;
dissolved in 0.85% NaCl, adjust to pH 7.4); group 3mice were injected i.
p.with a lethal dose of LPS (37.5mg/kg); group 4micewere injected i.p.
with ESeroS-GS (100mg/kg) 3 h before administration of LPS (37.5mg/
kg); group 5 mice were injected i.p. with LPS (37.5 mg/kg) for 3 h and
then injected i.p. with ESeroS-GS (100 mg/kg). Survival was monitored
every 3 h over the course of 120 h.Mantel–Haenszel log rank tests were
performed and Kaplan–Meier survival curves were generated [20].
2.4. Immunodetection of cytokine secretion
RAW264.7 cells were incubated with or without ESeroS-GS for 30
min, and stimulated with LPS for 8 h. Cell culture supernatants were
harvested to measure the levels of cytokines. In experiments used to
determine serum levels of cytokines, mice were treated with LPS and/
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administration of LPS. The accumulation of the proinﬂammatory
cytokines TNF-α, IL-1β and IL-6 in cell culture supernatants or sera
was measured using sandwich ELISA kits (R&D Systems; Minneapolis,
MN, USA) according to the manufacturer's protocols [38]. Data
represent at least three independent experiments.
2.5. EPR detection of nitric oxide production
Direct evidence for the production of nitric oxide in LPS-activated
macrophages was provided by EPR spin trapping using the ferrous
diethyldithiocarbamate complex [Fe2+(DETC)2] as the spin trap.
Although nitric oxide is a paramagnetic compound, it is EPR silent
at room temperature in solution. However, when it is trapped with
[Fe2+(DETC)2], the resulting complex [ON-Fe2+(DETC)2] is ESR-
detectable at low temperature. Upon enrichment with organic
solvents such as ethyl acetate, the hydrophilic [ON-Fe2+(DETC)2]
complex can be detected at room temperature.
The experimental procedure used for nitric oxide detection has
been described elsewhere [21]. Brieﬂy, 2×107 RAW264.7 cells were
stimulated with 1 μg/ml LPS for 12 h. The spin-trapping agent,0
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means±SEM (n=3; *, pb0.01). (E) ESeroS-GS inhibits iNOS promoter activity. piNOS-LUC and pRL-TK-cotransfected cells were treated with the indicated concentrations of ESeroS-
GS for 30 min before stimulation with 1 μg/ml LPS for 2 h. The ﬁreﬂy and Renilla luciferase activities in the cell lysates were detected, and the former activity was normalized to the
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CCT ACT TCA CAA GTC-3′, and reverse: 5′-ACT AGG TTT GCC GAG TAG-
3′ (length of PCR product: 354bp); iNOS forward: 5′-GTG TTC CAC
CAGGAG ATG TTG-3′, and reverse: 5′-CTC CTG CCC ACT GAG TTC GTC-
3′ (length of PCR product: 576 bp); GAPDH forward: 5′-GAA GGG TGG
GGC CAA AAG-3′, and reverse: 5′-GGA TGC AGG GAT GAT GTT CT-3′
(length of PCR product: 295 bp). PCR products were visualized by
electrophoresis on 1.5% agarose gels stained with ethidium bromide.
2.7. Luciferase reporter assays
A ﬁreﬂy luciferase gene under the control of the iNOS promoter,
piNOS-LUC (a generous gift from Dr. Jih-Pyang Wang, Graduate
Institute of Pharmaceutical Chemistry, China Medical University), and
a ﬁreﬂy luciferase gene under the control of four tandem copies of the
consensus NF-κB site, pNF-κB-LUC (Clontech, Mountain View, CA,
USA), were used to quantify iNOS promoter activity and NF-κB
transcriptional activity, respectively [39]. A Renilla luciferase reporter
under the control of the herpes simplex virus thymidine kinase
promoter, pRL-TK (Promega), was used as an internal control to
normalize the reporter gene activity. RAW264.7 cells were transiently
transfected by Lipofectamine 2000TM (Invitrogen). Twenty-four hours
later, the culture medium was replaced, and cells were treated with
ESeroS-GS for 30 min followed by stimulation with LPS for 2 h. Then
the cells were lysed, and the luciferase activity was determined by a
Sirius luminometer using a dual-luciferase reporter assay (Promega)
according to the manufacturer's instructions.
2.8. Electrophoretic mobility shift assays
Electrophoretic mobility shift assays (EMSA) were performed as
described byHou and coworkers [40], withminormodiﬁcations. In brief,
biotinylated probes for NF-κB (5′-AGT TGA GGG GAC TTT CCC AGG C-3′
and 3′-TCA ACT CCC CTG AAA GGG TCC G-5′) were synthesized, and
nuclear proteins were extracted from RAW264.7 cells using NE-PER
nuclear protein extraction kits (Pierce, Beijing, China). EMSA assays of
NF-κB activationwere carried out using non-radioactive LightShift EMSA
kits (Pierce) following the manufacturer's instructions. In brief, biotin-
labeled DNA probes were incubated with nuclear extracts for 20 min in
the presence of 0.05% Nonidet P-40 and 1 μg/μl dI-dC. Nuclear extracts
were then subjected to 6% native PAGE and transferred to a nylon
membrane. After cross-linkingbyUV light, themembranewas visualized
by chemiluminescence and recorded with Kodak X-OMAT ﬁlm.
2.9. Cell fractionation
Whole-cell lysates were prepared by lysing RAW264.7 cells in a
buffer containing 1% Nonidet P-40, 0.25% sodium deoxycholate, 150
mM NaCl, 10 mM Tris, 1 mM EGTA, 1 mM Na3VO4, 1 mM NaF, 1 mM
phenylmethylsulfonyl ﬂuoride (PMSF), 1 μg/ml leupeptin, and 1 μg/ml
aprotinin at 4 °C for 30 min [41].Fig. 3. ESeroS-GS inhibits the activation of NF-κB. (A) ESeroS-GS reduces the binding comp
ESeroS-GS for 30 min and then stimulated with 1 μg/ml LPS for 2 h. The binding complex of
speciﬁc biotin-labeled oligonucleotides. (B) ESeroS-GS decreases the NF-κB-dependent repo
with the indicated concentrations of ESeroS-GS for 30min before stimulation with 1 μg/ml LP
the former activity was normalized to the latter activity. Values represent means±SEM (n=
RAW264.7 cells were incubated with 50 μM ESeroS-GS for 30 min, and then stimulated with
α were determined by Western blotting. The upper panel shows a representative Western b
IκB-α protein normalized to β-tubulin. Values represent means±SEM (n=3; *, pb0.01). (
incubated with 50 μM ESeroS-GS for 30 min, and then stimulated with 1 μg/ml LPS for the le
blotting. The upper panel shows a representativeWestern blot, and the lower panel shows th
means±SEM (n=3; *, pb0.01). (E) ESeroS-GS suppresses the phosphorylation of IKK an
stimulated with 1 μg/ml LPS for 5 min. The levels of phosphorylated and total IKKα/β and
Western blot, and the lower panel shows the densitometric analysis of phosphorylated IKKα
(F) ESeroS-GS suppresses the phosphorylation of IRAK-1. RAW264.7 cells were incubated wi
phosphorylated and total IRAK-1 were determined by Western blotting. The upper pane
densitometric analysis of phosphorylated IRAK-1 normalized to β-tubulin. Values represenCytosolic andnuclearproteinswereextracted fromRAW264.7 cells as
described previously [21]. Brieﬂy, 107 cells were lysed with 300 μl buffer
A (0.2% Nonidet P-40, 10 mM Hepes, 10 mM KCl, 100 μM EDTA, 100 μM
EGTA, 2 mMNaF, 1 mM PMSF, 1 μg/ml aprotinin and 1 μg/ml leupeptin)
at 4 °C for 15 min. After centrifugation at 12,000 × g for 15 min, the
supernatant containing cytosolic proteins was collected. The pellet was
washed once with buffer A and then suspended in 100 μl of buffer B (20
mMHepes, 390mMNaCl, 1mMEDTA, 1mMEGTA, 2mMNaF, and2mM
phenylmethylsulfonyl ﬂuoride). After centrifugation at 12,000 × g for 15
min, the supernatant was collected and used as nuclear proteins.
Lipid raft and non-raft fractions of RAW264.7 cells were prepared
by sucrose gradient centrifugation [42]. Cells (5 × 107) were lysed at 4
°C in 2 ml TNE buffer (25 mM Tris, 150 mM NaCl, 5 mM EDTA)
containing 1% Triton X-100, 1mMNa3VO4, 100 μMDTT, 200 μMPMSF,
1 μg/ml leupeptin, 1 μg/ml aprotinin, 50 mM NaF, 10 mM sodium
pyrophosphate, 2.5 μg/ml pepstatin A, and 1 mM benzamidine.
Lysates were then mixed with 2.5 ml 80% sucrose in TNE. Samples
were then overlaid with 7 ml 35% sucrose in TNE followed by 3 ml 5%
sucrose in TNE. Lysates were then spun for 18 h at 100,000 × g at 4°C.
The gradient was then divided into 10 fractions, with fractions 2–4
representing the lipid raft fraction, and fractions 6–9 representing the
non-raft fraction. Protein within the combined fractions was precip-
itated with trichloroacetic acid and then resuspended in 200 μl TNE.
2.10. Western blotting
Western blotting was performed using whole-cell lysates, cyto-
solic proteins, nuclear proteins, and lipid raft or non-raft fractions
isolated from RAW264.7 cells. Samples were resolved by 10% SDS-
PAGE, transferred to polyvinylidene ﬂuoride (PVDF) membranes, and
probed with primary antibodies. The membranes were incubated
with peroxidase-conjugated secondary antibodies and visualized
using a chemiluminescent substrate (ECL; GE Amersham Pharmacia,
Beijing, China) and Kodak X-OMAT ﬁlm (Rochester, NY, USA).
2.11. Analysis of LPS–FITC binding to RAW264.7 cells
RAW264.7 cells (104 cells/chamber) were plated in an 8-chamber
Lab-Tek-chambered coverglass system (Nalgene Nunc, Rochester, NY,
USA) and cultured overnight. Cells were pretreated with or without
50 μM of ESeroS-GS at 37 °C for 30 min, and then incubated with LPS–
FITC (1 mg/ml) for 15 min. The cells were washed and covered with
fresh medium. The uptake of LPS–FITC was analyzed using ﬂuores-
cence confocal microscopy [43].
2.12. Data analysis
All data are expressed as the mean±SD unless otherwise indicated.
Differences between groups were compared by analysis of variance
followed by post hoc Bonferroni tests to correct formultiple comparisons.
Differences were considered to be statistically signiﬁcant at pb0.05.lex of NF-κB-DNA. RAW264.7 cells were treated with the indicated concentrations of
NF-κB-DNA was measured by electrophoretic mobility shift assay (EMSA) with NF-κB-
rter gene expression. The pNF-κB-LUC and the pRL-TK-cotransfected cells were treated
S for 2 h. The ﬁreﬂy and Renilla luciferase activities in the cell lysates were detected, and
3; *, pb0.01). (C) ESeroS-GS suppresses the phosphorylation and degradation of IκB-α.
1 μg/ml LPS for the lengths of time indicated. The levels of phosphorylated and total IκB-
lot, and the lower panel shows the densitometric analysis of phosphorylated and total
D) ESeroS-GS inhibits the nuclear translocation of p65 and p50. RAW264.7 cells were
ngths of time indicated. The levels of nuclear p65 and p50 were determined byWestern
e densitometric analysis of p65 and p50 protein normalized to lamin B. Values represent
d TAK1. RAW264.7 cells were incubated with 50 μM ESeroS-GS for 30 min, and then
TAK1 were determined by Western blotting. The upper panel shows a representative
/β and TAK1 normalized to β-tubulin. Values represent means±SEM (n=3; *, pb0.01).
th 50 μMESeroS-GS for 30 min, and then stimulated with 1 μg/ml LPS for 5min. Levels of
l shows representative results of Western blotting, and the lower panel shows the
t means±SEM (n=3; *, pb0.01).
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3.1. ESeroS-GS inhibits the production of inﬂammatory cytokines in
RAW264.7 macrophages
To test whether ESeroS-GS affected the release of proinﬂammatory
cytokines in murine RAW264.7 macrophages, cells were pretreatedA
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ment of cells with ESeroS-GS in a dose-dependent manner (Fig. 1B
and C). Interestingly, neither α-tocopherol nor glutathione, the two
precursors of ESeroS-GS, showed inhibitory effects on cytokine
production, even at high concentrations.
To examine whether ESeroS-GS affected the release or the
production of proinﬂammatory cytokines, we compared inﬂammato-
ry cytokine mRNA levels. RT-PCR was performed on mRNA isolated
from RAW264.7 cells stimulatedwith LPS for different lengths of time.
Treatment with LPS alone induced a marked increase in the mRNA
levels of TNF-α, IL-1β, and IL-6 compared with non-treated cells.
Pretreatment with ESeroS-GS (50 μM) signiﬁcantly reduced the levels
of IL-1β, IL-6 and TNF-α mRNAs in LPS-stimulated cells (Fig. 1D).
These results indicate that ESeroS-GS affects the transcript levels of
several inﬂammatory cytokines.
3.2. ESeroS-GS down-regulates the expression of iNOS and decreases the
production of NO in RAW264.7 macrophages
We measured LPS-induced production of NO in RAW264.7 cells by
ESR spin trapping. A three-line ESR spectrum corresponding to the [ON-
Fe2+(DETC)2] complex at g=2.035 was observed in RAW264.7 cells
treated with LPS (1 μg/ml) for 12 h (Fig. 2A), suggesting that stimulated
macrophages do generate nitric oxide. After pretreatmentwith 20 or 50
μMof ESeroS-GS, the signal intensity of the [ON-Fe2+(DETC)2] complex
decreased signiﬁcantly as shown in Fig. 2B, suggesting that ESeroS-GS
inhibited NO production in RAW264.7 cells in a dose-dependent
manner.
To investigate whether inhibition of NO production is due to a
reduction in iNOS expression, we examined the effect of ESeroS-GS on
the expression of the iNOS gene using RT-PCR and Western blotting.
After exposure to 1 μg/ml LPS, the expression of iNOSwas induced in a
time-dependent manner as shown in Fig. 2C and D. Pretreatment with
50 μM of ESeroS-GS before LPS treatment signiﬁcantly inhibited the
expression of iNOS (Fig. 2C and D). In addition, ESeroS-GS decreased
LPS-induced iNOS promoter activity in a dose-dependent manner as
measured using a reporter gene assay (Fig. 2E). These results imply
that ESeroS-GS down-regulates the expression of iNOS and decreases
the production of NO, and that blockading the transcriptional process
plays a critical role in the inhibition of iNOS expression.
3.3. ESeroS-GS attenuates LPS-induced NF-κB activation by suppressing
IRAK/TAK/IKK phosphorylation
Since activation of NF-κB is responsible for the production of
proinﬂammatory cytokines and NO upon LPS stimulation, we
hypothesized that the NF-κB signaling pathway may be involved in
ESeroS-GS-mediated inhibition of proinﬂammatory cytokines and
iNOS expression. To demonstrate this, we determined the effect of
ESeroS-GS on NF-κB transcriptional activity by electrophoretic
mobility shift assays (EMSA) with NF-κB-speciﬁc biotin-labeled
oligonucleotides, which were derived from NF-κB binding sequences
in the murine iNOS promoter. RAW264.7 mouse macrophages were
pretreated with or without ESeroS-GS for 30 min, stimulated with LPS
for 2 h, and then subjected to EMSA. We found that LPS caused a
marked increase in the binding of NF-κB to DNA (Fig. 3A, NF-κB-DNA
in lane 2). ESeroS-GS at a ﬁnal concentration of 50 μM signiﬁcantly
inhibited the binding of NF-κB to biotin-labeled DNA probes (Fig. 3A,
lane 3), suggesting that the LPS-induced transcriptional activity of NF-
κB was signiﬁcantly reduced by treatment with ESeroS-GS. The
expression of reporter genes in cells cotransfected with pNF-κB-LUC
and pRL-TK was also analyzed. Consistent with the EMSA assay, the
expression of NF-κB luciferase activity was inhibited in a concentra-
tion-dependent manner by ESeroS-GS (Fig. 3B). These results indicate
that ESeroS-GS might suppress expression of proinﬂammatorycytokine and iNOS genes by blocking the binding of NF-κB to the
promoter regions of these genes.
In quiescent macrophages, NF-κB is inactivated in the cytosol via
binding to IκB. LPS initiates NF-κB activation via the phosphorylation
and subsequent degradation of IκB, and NF-κB is then translocated to
the nucleus where it binds to DNA [10]. Here, we investigated the
effect of ESeroS-GS on IκB-α turnover in response to LPS stimulation.
RAW264.7 cells were pretreatedwith 50 μMESeroS-GS for 30min and
then treated with 1 μg/ml LPS for different lengths of time. LPS caused
a rapid (~15 min after LPS stimulation) phosphorylation and
degradation of IκB-α protein (Fig. 3C) in RAW264.7 cells which
could be suppressed by pretreatment of cells with 50 μMof ESeroS-GS.
These results suggest that ESeroS-GS might inhibit NF-κB activation
by blocking LPS-induced IκB-α phosphorylation and degradation. To
conﬁrm this, we further examined the nuclear translocation of p65/
Rel A and p50. In agreementwith the above IκB-α degradation results,
LPS resulted in marked p65/Rel A and p50 translocation from the
cytosol to the nucleus, and ESeroS-GS (50 μM) signiﬁcantly sup-
pressed the nuclear translocation of p65/Rel A and p50 (Fig. 3D).
Since the phosphorylation of IκB proteins is regulated by the IκB
kinases, IKKα/β, and phosphorylation of IKKα/β is further regulated
by upstream factors such as TAK1, we next attempted to determine
whether the inhibition effect of ESeroS-GS on LPS-induced NF-κB
activation occurs through the TAK1/IKKα/β signaling pathway.
Immunoblots showed that, in agreement with our results on the
phosphorylation and degradation of IκB-α, LPS causes phosphoryla-
tion of TAK1 and IKKα/β (Fig. 3E), while ESeroS-GS pretreatment
signiﬁcantly decreases the LPS-stimulated phosphorylation of TAK1
and IKKα/β.
Upon binding of TLR-4 to LPS, the cytoplasmic region of TLR-4
recruits MyD88, which links TLR-4 to IRAK-1. IRAK-1 binds TRAF6 and
then initiates a cascade of events leading to the phosphorylation of
TAK1. We assayed the effects of ESeroS-GS on LPS-induced phos-
phorylation of IRAK-1. ESeroS-GS pretreatment signiﬁcantly de-
creased LPS-stimulated phosphorylation of IRAK-1, as shown in
Fig. 3F. The above data suggest that the IRAK-1/TAK1/IKKα/β
signaling pathway is involved in the inhibition of NF-κB activation
by ESeroS-GS.
3.4. ESeroS-GS inhibits the binding of LPS–FITC to RAW264.7 macrophages
and attenuates LPS-induced lipid raft mobilization of CD14 and TLR-4
As the activation of macrophages by LPS starts when LPS binds to
the cell membrane, we investigated the effects of ESeroS-GS on the
binding of LPS to RAW264.7 macrophages. RAW264.7 cells were
incubated with LPS–FITC (1 μg/ml) in the presence or absence of
ESeroS-GS, and the uptake of FITC-labeled LPS was traced by confocal
microscopy. As shown in Fig. 4A, ESeroS-GS inhibits LPS–FITC binding
to the macrophages signiﬁcantly.
Since CD14, the primary receptor of LPS which is mainly expressed
in macrophages, is responsible for the binding and internalization of
LPS [35], and since the interaction of the LPS–CD14 complex with the
transmembrane protein TLR-4 initiates intracellular signaling
[36,37], we examined whether ESeroS-GS inhibits LPS binding by
CD14/TLR-4-related mechanisms. However, no changes in CD14 and
TLR-4 expression were noted following ESeroS-GS pretreatment
(Fig. 4B). Since the ligation of CD14 by LPS and the recruitment of
multiple signaling molecules within the lipid rafts are the basis for
cellular activation by LPS, we then investigated the effects of
ESeroS-GS on the distribution of CD14 and TLR-4 in lipid raft
fractions. The lipid raft and non-raft fractions were isolated from
RAW264.7 cells by discontinuous sucrose density gradient centrifu-
gation. As seen from Fig. 4C, the lipid rafts were mainly present in
fraction 2 and, to a lesser extent, in fractions 1 and 3, as determined
by the signal intensity of the lipid raft marker protein ﬂotillin-1 and
marker lipid ganglioside GM1. The distribution patterns of GM1,
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Fig. 4. ESeroS-GS inhibits LPS signaling by impairing themobilization of CD14 and TLR-4 to lipid rafts. (A) ESeroS-GS inhibits the binding of LPS to RAW264.7 macrophages. RAW264.7 cells
were incubated with 50 μM ESeroS-GS for 30 min, and then stimulated with 1 μg/ml FITC-LPS for 15 min. The binding of FITC-LPS to macrophages was observed by confocal microscopy.
(B) ESeroS-GS has noeffect on the expression of CD14 andTLR-4. RAW264.7 cellswere incubatedwith 50 μMESeroS-GS for 30minand then stimulatedwith 1 μg/ml LPS for 5min. The levels
ofCD14andTLR-4weredeterminedbyWesternblotting. Theupperpanel shows representativeresults ofWesternblotting, and the lowerpanel shows thedensitometric analysis ofCD14and
TLR-4normalized toβ-actin. Values representmeans±SEM(n=3; *,pb0.01). (C)ESeroS-GSdoesnot affect thebuoyancyof lipid rafts. RAW264.7cellswere incubatedwith50μMESeroS-GS
for 30min and then stimulatedwith 1 μg/ml LPS for 5min. The lipid raft andnon-raft fractionswere isolated by discontinuous sucrose density gradient centrifugation and the distribution of
GM1, ﬂotillin-1 and β-actin in different fractionswas analyzed byWestern blotting. (D) ESeroS-GS inhibits themobilization of CD14 and TLR-4 to lipid rafts. RAW264.7 cells were incubated
with50 μMESeroS-GS for 30min, and then stimulatedwith1 μg/ml LPS for 5min.ThemobilizationofCD14andTLR-4 to lipid raftswasanalyzedbyWesternblotting.Theupperpanel showsa
representativeWestern blot, and the lower panel shows the densitometric analysis of CD14 and TLR-4 normalized to ﬂotillin-1. Values represent means±SEM (n=3; *, pb0.01).
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ESeroS-GS or LPS, indicating that ESeroS-GS and LPS do not affect
the buoyancy of lipid rafts in general (Fig. 4C). Raft fractions
(fractions 1–3) and non-raft fractions (fractions 4–10), deﬁned
according to ﬂotillin-1 or GM1 distribution patterns, were combined
separately and proteins were concentrated by TCA precipitation for
detection of CD14 and TLR-4. The speciﬁcity of raft and non-raft
fractions was further veriﬁed by the consistent detection of ﬂotillin-
1 only within the raft fraction and β-actin only within the non-raft
fraction. As shown in Fig. 4D, relatively low CD14 and undetectable
TLR-4 concentrations were present within the lipid raft prior to LPS
exposure; however, exposure to LPS resulted in a signiﬁcant
increase in CD14 and TLR-4 protein within the lipid raft. This effect
was attenuated by pretreatment with ESeroS-GS. These data suggest
that the suppressive effects of ESeroS-GS on LPS-induced NF-κB
activation might be related to the fact that ESeroS-GS interfered
with LPS-induced redistribution of CD14 and TLR-4 to lipid raft
fractions.3.5. ESeroS-GS increases the life span of sepsis-bearing mice
Having shown that ESeroS-GS efﬁciently inhibits LPS stimulation
of proinﬂammatory factors in vitro, we next investigated whether
ESeroS-GS protects animals from LPS lethal toxicity in a sepsis model.
C57BL/6J mice were injected with ESeroS-GS (100 mg/kg) or saline
and then challenged i.p. with LPS. Pretreatment of mice with ESeroS-
GS before LPS administration signiﬁcantly attenuated the increase in
serum cytokine levels (Fig. 5A–C).A
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Fig. 5. ESeroS-GS in vivo affects serum proinﬂammatory cytokine concentration and increase
with ESeroS-GS (100mg/kg) or saline and then challenged i.p. with a lethal dose of LPS (37.5
proinﬂammatory cytokine TNF-α in serum samples was measured using an R&D System
measurement. (C) IL-6 measurement. (D) ESeroS-GS increases life span of sepsis-bearing mi
injected i.p. with saline; group 2mice were injected i.p. with ESeroS-GS (100 mg/kg of body w
lethal dose of LPS (37.5 mg/kg); group 4 mice were injected i.p. with ESeroS-GS (100 mg/kg)
(37.5 mg/kg) for 3 h and then injected i.p. with ESeroS-GS (100mg/kg). Survival was monito
of 120 h. The Kaplan–Meier survival curve of group 3 (marked as LPS), group 4 (marked asEffects of ESeroS-GS on the life span of mice treated with a lethal
dose of LPS were further investigated. All mice administered with LPS
alone died in 48 h. However, pretreatment with ESeroS-GS before LPS
injection increased survival to 66.7% at 48 h (Fig. 5D) and 58.3% at 120
h, and posttreatment with ESeroS-GS after LPS injection increased
survival to 41.6% at 48 h (Fig. 5D) and 16.7% at 120 h, suggesting that
ESeroS-GS increases life span of sepsis-bearing mice.
4. Discussion
LPS stimulation elicits a cascade leading to the activation of NF-κB
and the production of proinﬂammatory molecules (including cyto-
kines, nitric oxide, and prostaglandins). However, unbalanced or
overproduction of such factors may lead to septic shock, often
resulting in death [16]. Accordingly, inhibition of the LPS-stimulated
signal transduction cascade might be a promising target for the
treatment of sepsis. We here provide direct evidence that the sodium
salt of γ-L-glutamyl-S-[2-[[[3,4-dihydro-2,5,7,8-tetramethyl-2-
(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl]oxy]carbonyl]-3-
[[2-(1H-indol-3-yl)ethyl]amino]-3-oxopropyl]-L-cysteinylglycine
(ESeroS-GS), a novel α-tocopherol derivative, reduces the transcrip-
tion of TNF-α, IL-1β, IL-6 and iNOS genes in LPS-stimulated RAW264.7
macrophages, and inhibits the release of these inﬂammatory factors
(Figs. 1 and 2). In addition, we show that ESeroS-GS inhibits LPS-
stimulated production of proinﬂammatory cytokines in vivo and
increases the life span of sepsis-bearing mice (Fig. 5).
A broad range of antioxidants, including derivatives and analogs of
tocopherols, could act as anti-inﬂammatory agents in vitro and in vivo,
probably via a redox-dependent NF-κB signaling pathway [22–24]. WeLPS− + − +
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activation in RAW264.7 cells. The transcriptional activity of NF-κB was
assessed in cells transiently transfected with a pNF-κB-LUC reporter
construct containing four tandem copies of the NF-κB consensus
sequence linked to the ﬁreﬂy luciferase gene. ESeroS-GS signiﬁcantly
inhibited the transcriptional activity of NF-κB (Fig. 3B). EMSA data also
revealed that ESeroS-GS inhibited the binding complex of NF-κB-DNA
present in the iNOS promoter (Fig. 3A). These ﬁndings are consistent
with our previous report that ESeroS-GS inhibits iNOS expression in
astrocytes via a NF-κB-dependent mechanism [41]. Western blotting
results further revealed that the inhibition of NF-κB activation by
ESeroS-GSmight result from the suppression of IRAK-1, TAK1 and IκB-α
phosphorylation (Fig. 3E), and subsequent inhibition of IκB-α degrada-
tion (Fig. 3C) and reduction of p65 and p50 nuclear translocation
(Fig. 3D).
We then looked for the upstreammolecule targeted by ESeroS-GS,
by downregulating the LPS-stimulated activation of IRAK-1 cascades.
ESeroS-GS effectively attenuated the binding and the internalization
of FITC–LPS (Fig. 4A), as observed by laser confocal scanning
microscopy; however, the expression of CD14 and TLR-4, the primary
receptor of LPS in macrophages, was not affected by ESeroS-GS
treatment (Fig. 4B). By analyzing the partitioning of CD14 and TLR-4
in different plasma membrane microdomains, we found that
pretreatment of ESeroS-GS signiﬁcantly alters the LPS-induced
translocation of CD14 and TLR-4 into lipid rafts (Fig. 4D) without
affecting the buoyancy of lipid rafts in general (Fig. 4C).
An important ﬁnding of this study is that ESeroS-GS signiﬁcantly
inhibits the activation of macrophages via lipid raft-dependent
mechanisms. Although surface expression of CD14 and TLR-4 has
not been shown to be affected by ESeroS-GS pretreatment, the LPS-
induced translocation of CD14 and TLR-4 into lipid rafts was inhibited
by ESeroS-GS, and thus the LPS-induced assembly of the TLR-4
complex in the lipid raft microdomains was altered.Sphingomyelin
E
Fig. 6. Molecular structures of sphingomLipid rafts are mainly composed of sphingolipids and cholesterol
(Fig. 6). The most prevalent component of sphingolipids in the cell
membrane is sphingomyelin, which is composed of a highly hydropho-
bic ceramide moiety and a hydrophilic phosphorylcholine headgroup.
The small cholesterol sterol-ring system and the ceramide moiety of
sphingomyelin interact via hydrogen bonds and hydrophobic van der
Waals interactions. Further hydrophilic interactions between sphingo-
lipid headgroups promote the lateral association of sphingolipids and
cholesterol. These interactions result in the separation of sphingolipids
and cholesterol from other phospholipids in the cell membrane and
thereby the formation of distinctmicrodomains. In thesemicrodomains,
cholesterol exerts a stabilizing role byﬁlling the voids between the large
and bulky sphingolipids. It is this cholesterol-sphingolipid interaction
that determines the transition of these microdomains into a liquid-
ordered or even gel-like phase, which is a unique characteristic of lipid
rafts.
Lipid rafts are thought to dynamically organize cellular signaling
events triggered by extracellular stimuli [25,26]. The dynamic remodel-
ing of lipid rafts during proximal LPS signaling is believed to actively
recruit non-raft proteins to rafts as well as to enrich selected raft-
resident proteins [44]. Initial binding of LPS to CD14 results in the
activation of acid sphingomyelinase and the consequent liberation of
ceramide from the sphingomyelin [45]. Ceramide, which has a special
ability to fuse membranes, appears to play important roles in the
assembly of theTLR-4 complex [46]. Since treatment with antioxidants
impairs sphingomyelinase activation and ceramide production [47],
while ESeroS-GS inhibits macrophage activation via a lipid raft-
dependent mechanism, we speculated whether ESeroS-GS acts as an
antagonist of ceramide in the remodeling of lipid rafts. ESeroS-GS
comprisesα-tocopherol and glutathione linked to the core succinic acid,
and its unique structure endows ESeroS-GS both hydrophilic and
hydrophobic characteristics. However, we found that neither ESeroS-GS
nor its precursors (α-tocopherol and glutathione) have apparent effectsCholesterol
SeroS-GS
yelin, cholesterol, and ESeroS-GS.
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Fig. 7. Hypothesis of the effects of ESeroS-GS on lipid rafts.
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model membrane systems enriched with sphingomyelin and choles-
terol was also not affected by ESeroS-GS, α-tocopherol or glutathione
(data not shown). By analyzing the partitioning of lipid raftmarkers, we
found that pretreatment of RAW264.7macrophageswith ESeroS-GS did
not affect the buoyancy of lipid rafts in general (Fig. 4D). These data
suggest that ESeroS-GS might not affect the lipid raft directly (Fig. 7)..
It has been reported that lipid rafts are targets of several
antioxidants, including (−)-epigallocatechin gallate (EGCG; a major
component of green tea polyphenols) [48,49], quercetin [50],
resveratrol [51], and tocopherol [52]. However, the underlying
mechanisms by which these antioxidants affect the lipid raft remains
an open question. Plant ﬂavonoids can inﬂuence the appearance and
development of rafts or raft-like membrane domains in cellular
membranes, and thus inﬂuence the lateral diffusion of lipid molecules
[53]. One recent hypothesis is that α-tocopherol partitions into
domains that are enriched in highly disordered polyunsaturated
phospholipid domains. These highly disordered domains which are
depleted in cholesterol are analogous, but organizationally antithet-
ical, to lipid rafts [54]. Domains that are enriched in either
sphingolipids and cholesterol (lipid rafts) or polyunsaturated phos-
pholipids (disordered domains) are both targets of redox signaling
[55], especially in macrophages [50,56].
In conclusion, we have demonstrated that ESeroS-GS can protect
mice from LPS-induced lethality. Moreover, ESeroS-GS inhibits the
production of proinﬂammatory factors in vivo and in vitro. Our ﬁndings
providenovel insights into themolecularmechanismsbywhichESeroS-
GS regulates inﬂammation and show that ESeroS-GS functions byregulating NF-κB activity through the suppression of lipid raft-
dependent assembly of TLR-4 complexes. How the novel antioxidant
ESeroS-GS disrupts the assembly of the TLR-4 complex in lipid rafts
remains unclear, and further investigation is required to determine the
precise site of ESeroS-GS action in the dynamic remodeling of lipid rafts.
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